Related Experiment Video
Updated: Mar 7, 2026
14:32
Using Visual and Narrative Methods to Achieve Fair Process in Clinical Care
Published on: February 16, 2011
24.9K
Culture and Process Change as a Priority for Patient Engagement in Medicines Development
Marc Boutin1, Lode Dewulf2, Anton Hoos3
1National Health Council, Washington, DC, USA.
Therapeutic Innovation & Regulatory Science
|February 25, 2017
Summary
Patient Focused Medicines Development (PFMD) is a global coalition prioritizing patient engagement in drug development. They identified four key areas for improvement: culture change, a global framework, information exchange, and training.
Area of Science:
- Pharmaceutical Sciences
- Patient Advocacy
- Health Policy
Background:
- Patient engagement (PE) is increasingly prioritized in healthcare, leading to numerous uncoordinated initiatives.
- Patient Focused Medicines Development (PFMD) is a multinational coalition of patients, patient organizations, and the pharmaceutical industry.
- PFMD emphasizes patient perspectives from the outset, ensuring equal collaboration and governance for patient groups.
Purpose of the Study:
- To outline PFMD's strategic approach to integrating patient perspectives early in the medicines development process.
- To identify and address key areas requiring focused effort for effective patient engagement.
Main Methods:
- Comprehensive mapping of existing patient engagement initiatives.
- Analysis of stakeholder needs to determine priority areas for intervention.
- Development of a global meta-framework for patient engagement.
Main Results:
- Identification of four priority areas essential for implementing patient engagement: culture and process change, a global meta-framework, information exchange, and training.
- PFMD has established a governance model ensuring parity for patient group members.
- Ongoing and planned activities within PFMD are aligned with these priority areas.
Conclusions:
- A structured, collaborative approach is crucial for advancing patient engagement in medicines development.
- Addressing the identified priority areas will facilitate a more integrated and effective patient engagement strategy.
- PFMD's model offers a unique platform for equal collaboration among patients, patient organizations, and the pharmaceutical industry.
Related Concept Videos
01:13Patient-centered Care
3.2K
Patient-centered care involves delivering care beyond inpatient hospitalization. Reflective practice can enhance a patient-centered approach. Reflective practice is a process of reasoning that considers all aspects of the present situation, including practicalities, learning from personal practice, and consideration of patient needs. Patients appreciate care decisions made while considering their input. Involving the patient in their care provides the patient with a sense of contribution rather...
3.2K
01:26Drug Administration and Therapy Phases: Overview
1.6K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.6K
01:11Clinical Trials: Overview
5.2K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.2K
01:28Preclinical Development: Overview
6.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.2K
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
389
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
389
01:26FDA Approved Drugs: Changes to Approved Drugs
301
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
301